BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12464652)

  • 1. HDM2 protein overexpression and prognosis in primary malignant melanoma.
    Polsky D; Melzer K; Hazan C; Panageas KS; Busam K; Drobnjak M; Kamino H; Spira JG; Kopf AW; Houghton A; Cordon-Cardo C; Osman I
    J Natl Cancer Inst; 2002 Dec; 94(23):1803-6. PubMed ID: 12464652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
    Polsky D; Bastian BC; Hazan C; Melzer K; Pack J; Houghton A; Busam K; Cordon-Cardo C; Osman I
    Cancer Res; 2001 Oct; 61(20):7642-6. PubMed ID: 11606406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
    Dai DL; Martinka M; Li G
    J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
    Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
    Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.
    Berger AJ; Camp RL; Divito KA; Kluger HM; Halaban R; Rimm DL
    Cancer Res; 2004 Dec; 64(23):8767-72. PubMed ID: 15574789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma.
    Mihic-Probst D; Kuster A; Kilgus S; Bode-Lesniewska B; Ingold-Heppner B; Leung C; Storz M; Seifert B; Marino S; Schraml P; Dummer R; Moch H
    Int J Cancer; 2007 Oct; 121(8):1764-70. PubMed ID: 17597110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.
    Natali PG; Nicotra MR; Winkler AB; Cavaliere R; Bigotti A; Ullrich A
    Int J Cancer; 1992 Sep; 52(2):197-201. PubMed ID: 1381702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of cerbB3 in naevi and malignant melanomas.
    Korabiowska M; Mirecka J; Brinck U; Hoefer K; Marx D; Schauer A
    Anticancer Res; 1996; 16(1):471-4. PubMed ID: 8615656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
    Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
    Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDM2 overexpression and focal loss of p14/ARF expression may deregulate the p53 tumour suppressor pathway in meningeal haemangiopericytomas. Study by double immunofluorescence and laser scanning confocal microscopy.
    Martínez JC; Palomino JC; Cabello A; Sepúlveda JM; de la Cámara AG; Ricoy JR
    Histopathology; 2005 Feb; 46(2):184-94. PubMed ID: 15693891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.
    Cymerman RM; Shao Y; Wang K; Zhang Y; Murzaku EC; Penn LA; Osman I; Polsky D
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27235387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities].
    Nepomniashchaia EM; Gusareva MA; Petrov SV
    Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of galectin-3 expression with melanoma progression and prognosis.
    Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
    Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
    Cressey R; Pimpa S; Tontrong W; Watananupong O; Leartprasertsuke N
    Cancer Lett; 2006 Feb; 233(2):232-9. PubMed ID: 15921850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
    Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
    J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.